Phase 2Data readout

ALKS 2680 (RDC-264177)

Idiopathic hypersomnia

ALKSAlkermes plc

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: ALKS 2680 (RDC-264177)
Development stage: Phase 2
Event type: Data readout
Indication: Idiopathic hypersomnia

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for ALKS 2680 (RDC-264177) in Idiopathic hypersomnia. The expected timing is based on the latest available company guidance and may change.

Development notes

07/27/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided